Search results
Added:
5 months ago
Source:
Radcliffe CVRM
A novel, once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, has demonstrated superior weight loss compared to placebo in adults with obesity or overweight and type 2 diabetes, according to results from the ATTAIN-2 trial.¹Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist, offering a potential alternative to injectable therapies for weight…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: David RamseyAmerican Diabetes Scientific Sessions, 21 June, 2024 – In a Phase III trial (SURMOUNT-OSA,NCT05412004)of patients with moderate-to-severe sleep apnea and obesity, tirzepatide demonstrated significant improvements in both sleep apnea scores as well as cardiometabolic risk factors including body weight, hsCRP and systolic blood pressure.SURMOUNT-OSA investigated tirzepatide’s…
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Dr Scott Isaacs, Prof Peter Rossing, Dr Muthiah Vaduganathan, Prof Stefan Anker and Dr Javed Butler discuss weight management for CRM disease.
View more
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Added:
7 months ago
Review Article
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof John Cleland, Prof Gerasimos Filippatos, Prof Ewa Jankowska, Prof David Wheeler, Dr Kieran Docherty discuss anaemia and iron deficiency.
View more
e-SPACE CRM 2025 – Day Two
Start date:
Apr 05, 2025
Broadcast
e-SPACE CRM 2025 – Day One
Start date:
Apr 04, 2025
Broadcast
Added:
2 months ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and…
View more
CaReMeLO Conference 2025
Start date:
May 31, 2025
End date:
May 30, 2025
Event
Added:
3 months ago